No abstract

No abstract

Citrus aurantifolia leaf essential oil was extracted via hydrodistillation, chemical composition of the oil was analyzed using gas chromatography-mass spectrometry and its antidiabetic potentials was assessed in alloxan-induced hyperglycaemic rats using metformin as the reference drug for comparison. Chemical analysis showed that D-limonene (57.84%) was the major constituent of the oil. Other notable compounds identified were neral (7.81%), linalool (4.75%), sulcatone (3.48%) and isogeraniol (3.48%). Intraperitoneal administration of C. aurantifolia oil (100 mg/Kg b.wt.) to hyperglycaemic rats for 14 days caused significant reduction in fasting blood and hepatic glucose, whereas hepatic concentration of glycogen was significantly increased. Also, improvement in dyslipidaemia was observed in C. aurantifolia essential oil-treated hyperglycaemic rats; serum concentration of total cholesterol, triacylglycerol and low density lipoprotein-cholesterol were significantly reduced and high density lipoprotein-cholesterol was increased, resulting in decreased predisposition of rats to cardiac risks. Antihyperglycaemic potential of administration of the oil was lower but compared favourably with the oral antihyperglycaemic agent used as reference antidiabetic drug. Overall, data from this study showed that essential oil from the leaf of C. aurantifolia grown in North-Central Nigeria is a D-limonene chemotype. The oil showed considerable glucose lowering effect as well as the potential to ameliorate hyperglycaemia-induced dyslipidaemic complications in alloxanized rats.

This study was aimed at assessing the potential of essential oil from the leaf of Hoslundia opposita in the treatment of diabetes. Forty-eight rats (Rattus norvegicus) were randomized into two groups; nondiabetic and diabetic groups, each with four subgroups. Animals in the diabetic group were induced with diabetes using a single dose of alloxan monohydrate, 160 mg/kg body weight (b. wt.). The rats were treated with 110 and 220 mg/kg b. wt. of the essential oil. All treatments were administered, intraperitoneally, once a day for 4 days. In the nondiabetic condition, there was no effect of the oil on fasting blood glucose (FBG) levels in rats. In diabetic rats, the oil caused a significant reduction in FBG levels. Treatment with 110 mg/kg b. wt. of the oil reduced FBG almost to the normoglycemic level by day 4 and the overall glucose excursion during a 3-h intraperitoneal glucose tolerance test approached the baseline level at 120 min. Also, hepatic glycogen was significantly higher, while the glucose concentrations were lower in the diabetic-treated group when compared with the diabetic untreated group. Histological examinations revealed a mildly distorted architecture of the pancreatic islets β-cells of diabetic rats treated with the oil, while those of the untreated rats were severely degenerated. Overall, the in vivo antihyperglycemic activity of the essential oil may prove to be of clinical importance in the management of type 2 diabetes.

Concoctions containing extract from Cocos nucifera husk fiber are used in Nigeria by traditional medicine practitioners for management of diabetes and its associated complications. Preliminary antidiabetic study was designed to validate the folkloric usage of the plant extract. Dried coconut husk fiber was pulverized and extracted with methanol, followed by partitioning of the methanolic extract in ethyl acetate. Phenolic content, radical scavenging activity and antioxidant capacity as well as inhibitory effects of C. nucifera methanolic (CN‐M) extract and its ethyl acetate (CN‐E) fraction on pancreatic α‐amylase and lipid peroxidation were determined. Total phenolic content and antioxidant capacity of CN‐E fraction were significantly higher than that of CN‐M extract, whereas there was no significant difference in their ability to scavenge free radicals. The CN‐E fraction also exhibited higher in vitro and in vivo inhibitory effects on α‐amylase activity and lipid peroxidation; reducing blood glucose level within 5 days following intraperitoneal administration of the C. nucifera extract to alloxan‐induced hyperglycemic rats. The phenolic‐rich extracts from coconut husk can be further explored as nutraceutical supplement in food formulation for diabetic patients.

Application of supercritical carbon dioxide as an alternative solvent for microformulation of the volatile unstable drug, eucalyptol in polymeric composites.

The antidiabetic potentials of Heliotropium indicum L. leaf aqueous (HILA) extract used for the management of diabetes by Traditional Medicinal Practitioners (TMPs) in Nigeria was assessed. Alloxan (ALX)-induced hyperglycaemic rats were orally administered with known folkloric dosage of 30 and 75 mg/kg b. wt. of HILA extract, once a day, for 14 days. Fasting blood glucose (FBG) levels were monitored and pancreatic histology was examined. Net hepatic glycogen (GLY) concentration and lipid profiles were also determined. Prior to treatment, ALX-induced hyperglycaemia (>250 mg/dL) was established in rats. Oral administration of 30 and 75 mg/kg b. wt. HILA extract to diabetic rats for 14 days caused significant reduction in FBG to baseline values observed in non-diabetic conditions. Treatment with HILA extract also showed improvement in lipid abnormalities observed in hyperglycaemic condition, levels of triglyceride, total cholesterol and LDL-cholesterol were significantly reduced and HDL-cholesterol increased resulting in improved artherogenic index. Hepatic GLY concentration was significantly increased in diabetic rat treated with the extract. Histological examinations showed degenerated and sparse pancreatic islets β-cells in non-treated diabetic rat, whereas microscopy of treated rats showed mild to normal architecture with enriched β-cells. Preliminary phytochemical profiling of the extract revealed the presence of alkaloids (2.54 mg/g), saponins (0.28 mg/g), phenols (0.04 mg/g) and anthraquinones (0.01 mg/g). Results from this study revealed that the aqueous leaf extract of H. indicum possesses not only antihyperglycaemic, but also antidyslipidemic activities, that may prove to be of clinical importance in the management of diabetes and associated secondary complications.

No abstract